A
The startup develops a cell death analysis technology that identifies and quantifies dead and dying cells in cancer patients, enabling real-time evaluation of treatment efficacy. This approach allows clinicians to personalize patient care and adapt therapies based on precise cellular responses, enhancing overall treatment outcomes.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a cell death analysis technology that identifies and quantifies dead and dying cells in cancer patients, enabling real-time evaluation of treatment efficacy. This approach allows clinicians to personalize patient care and adapt therapies based on precise cellular responses, enhancing overall treatment outcomes.